The role of chemokines in hepatitis C virus-mediated liver disease

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 4747-4779

  Brass, Anette ^a   Brenndörfer, Erwin Daniel ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

HCV; Hepatitis C treatment; Immune escape; Intrahepatic immunity; Liver cancer; Liver fibrosis

Indexed keywords

BETA INTERFERON; BOCEPREVIR; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; PATTERN RECOGNITION RECEPTOR; PROTEIN KINASE R; RETINOIC ACID INDUCIBLE PROTEIN I; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; CELL MIGRATION; CLINICAL TRIAL (TOPIC); HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INNATE IMMUNITY; LIVER CANCER; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LYMPHOCYTE HOMING; METABOLIC SYNDROME X; NATURAL KILLER CELL; NEUTROPHIL; PERSISTENT VIRUS INFECTION; PROTEIN EXPRESSION; REVIEW; TH1 CELL; BIOLOGICAL MODEL; CYTOLOGY; HEPACIVIRUS; HOST PATHOGEN INTERACTION; IMMUNE SYSTEM; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VIROLOGY;

ADAPTIVE IMMUNITY; CHEMOKINES; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; LIVER DISEASES; MODELS, IMMUNOLOGICAL;

EID: 84896476543     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15034747     Document Type: Review

References (199)

1. Lavanchy, D. The global burden of hepatitis C. Liver Int. 2009, 29, 74-81.
2. Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 2011, 17, 107-115.
3. Hoofnagle, J. H. Hepatitis C: The clinical spectrum of disease. Hepatology 1997, 26, 15S-20S.
4. Arzumanyan, A.; Reis, H. M. G. P. V.; Feitelson, M. A. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer 2013, 13, 123-135.
5. Moradpour, D.; Penin, F.; Rice, C. M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5, 453-463.
6. Penin, F.; Dubuisson, J.; Rey, F. A.; Moradpour, D.; Pawlotsky, J.-M. Structural biology of hepatitis C virus. Hepatology 2004, 39, 5-19.
7. Nakano, T.; Lau, G. M. G.; Lau, G. M. L.; Sugiyama, M.; Mizokami, M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 2011, 32, 339-345.
8. Micallef, J. M.; Kaldor, J. M.; Dore, G. J. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J. Viral Hepat. 2006, 13, 34-41.
9. Bode, J. G.; Brenndorfer, E. D.; Haussinger, D. Subversion of innate host antiviral strategies by the hepatitis C virus. Arch. Biochem. Biophys. 2007, 462, 254-265.
10. Loo, Y.-M.; Owen, D. M.; Li, K.; Erickson, A. K.; Johnson, C. L.; Fish, P. M.; Carney, D. S.; Wang, T.; Ishida, H.; Yoneyama, M.; et al. Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2006, 103, 6001-6006.
11. Saito, T.; Owen, D. M.; Jiang, F.; Marcotrigiano, J.; Gale, M., Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008, 454, 523-527.
12. Wang, N.; Liang, Y.; Devaraj, S.; Wang, J.; Lemon, S. M.; Li, K. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J. Virol. 2009, 83, 9824-9834.
13. Wu, J.; Lu, M.; Meng, Z.; Trippler, M.; Broering, R.; Szczeponek, A.; Krux, F.; Dittmer, U.; Roggendorf, M.; Gerken, G.; et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007, 46, 1769-1778.
14. Seki, E.; Brenner, D. A. Toll-like receptors and adaptor molecules in liver disease: Update. Hepatology 2008, 48, 322-335.
15. Li, K.; Li, N. L.; Wei, D.; Pfeffer, S. R.; Fan, M.; Pfeffer, L. M. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 2012, 55, 666-675.
16. Shimoike, T.; McKenna, S. A.; Lindhout, D. A.; Puglisi, J. D. Translational insensitivity to potent activation of PKR by HCV IRES RNA. Antivir. Res. 2009, 83, 228-237.
17. Arnaud, N.; Dabo, S.; Akazawa, D.; Fukasawa, M.; Shinkai-Ouchi, F.; Hugon, J.; Wakita, T.; Meurs, E. F. Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog. 2011, 7, e1002289.
18. Meylan, E.; Curran, J.; Hofmann, K.; Moradpour, D.; Binder, M.; Bartenschlager, R.; Tschopp, J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437, 1167-1172.
19. Li, X. D.; Sun, L.; Seth, R. B.; Pineda, G.; Chen, Z. J. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA 2005, 102, 17717-17722.
20. Li, K.; Foy, E.; Ferreon, J. C.; Nakamura, M.; Ferreon, A. C.; Ikeda, M.; Ray, S. C.; Gale, M., Jr.; Lemon, S. M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 2005, 102, 2992-2997.
21. Gale, M. J.; Korth, M. J.; Tang, N. M.; Tan, S. L.; Hopkins, D. A.; Dever, T. E.; Polyak, S. J.; Gretch, D. R.; Katze, M. G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997, 230, 217-227.
22. Pavio, N.; Taylor, D. R.; Lai, M. M. C. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J. Virol. 2002, 76, 1265-1272.
23. Taylor, D. R.; Shi, S. T.; Romano, P. R.; Barber, G. N.; Lai, M. M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999, 285, 107-110.
24. Ge, D.; Fellay, J.; Thompson, A. J.; Simon, J. S.; Shianna, K. V.; Urban, T. J.; Heinzen, E. L.; Qiu, P.; Bertelsen, A. H.; Muir, A. J.; et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461, 399-401.
25. Poordad, F.; McCone, J.; Bacon, B. R.; Bruno, S.; Manns, M. P.; Sulkowski, M. S.; Jacobson, I. M.; Reddy, K. R.; Goodman, Z. D.; Boparai, N.; et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364, 1195-1206.
26. Jacobson, I. M.; McHutchison, J. G.; Dusheiko, G.; di Bisceglie, A. M.; Reddy, K. R.; Bzowej, N. H.; Marcellin, P.; Muir, A. J.; Ferenci, P.; Flisiak, R.; et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364, 2405-2416.
27. Fried, M. W.; Buti, M.; Dore, G. J.; Flisiak, R.; Ferenci, P.; Jacobson, I.; Marcellin, P.; Manns, M.; Nikitin, I.; Poordad, F.; et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013, 58, 1918-1929.
28. Gane, E. J.; Stedman, C. A.; Hyland, R. H.; Ding, X.; Svarovskaia, E.; Symonds, W. T.; Hindes, R. G.; Berrey, M. M. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013, 368, 34-44.
29. Flisiak, R.; Jaroszewicz, J.; Parfieniuk-Kowerda, A. Emerging treatments for hepatitis C. Exp. Opin. Emerg. Drugs 2013, 18, 461-475.
30. Sulkowski, M. S.; Gardiner, D. F.; Rodriguez-Torres, M.; Reddy, K. R.; Hassanein, T.; Jacobson, I.; Lawitz, E.; Lok, A. S.; Hinestrosa, F.; Thuluvath, P. J.; et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014, 370, 211-221.
31. Westra, I. M.; Oosterhuis, D.; Groothuis, G. M. M.; Olinga, P. Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. Toxicol. Appl. Pharmacol. 2013, 274, 1-11.
32. Hong, F.; Chou, H.; Fiel, M. I.; Friedman, S. L. Antifibrotic activity of sorafenib in experimental hepatic fibrosis: Refinement of inhibitory targets, dosing, and window of efficacy in vivo. Digest. Dis. Sci. 2013, 58, 257-264.
33. Wilhelm, S. M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J. M.; Lynch, M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008, 7, 3129-3140.
34. Wang, Y.; Gao, J.; Zhang, D.; Zhang, J.; Ma, J.; Jiang, H. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J. Hepatol. 2010, 53, 132-144.
35. Bowen, D. G.; Walker, C. M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436, 946-952.
36. Bode, J. G.; Brenndorfer, E. D.; Haussinger, D. Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response. Biol. Chem. 2008, 389, 1283-1298.
37. Brenndorfer, E. D.; Sallberg, M. Hepatitis C virus-mediated modulation of cellular immunity. Arch. Immun. Ther. Exp. 2012, 60, 315-329.
38. Zlotnik, A.; Yoshie, O. The chemokine superfamily revisited. Immunity 2012, 36, 705-716.
39. Luster, A. D. Chemokines-Chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998, 338, 436-445.
40. Moser, B.; Wolf, M.; Walz, A.; Loetscher, P. Chemokines: Multiple levels of leukocyte migration control. Trends Immun. 2004, 25, 75-84.
41. Zhu, Y.; Murakami, F. Chemokine CXCL12 and its receptors in the developing central nervous system: Emerging themes and future perspectives. Dev. Neurobiol. 2012, 72, 1349-1362.
42. Zou, Y. R.; Kottmann, A. H.; Kuroda, M.; Taniuchi, I.; Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393, 595-599.
43. Calderon, L.; Boehm, T. Three chemokine receptors cooperatively regulate homing of hematopoietic progenitors to the embryonic mouse thymus. Proc. Natl. Acad. Sci. USA 2011, 108, 7517-7122.
44. Esche, C.; Stellato, C.; Beck, L. A. Chemokines: Key players in innate and adaptive immunity. J. Investig. Dermatol. 2005, 125, 615-628.
45. Dimberg, A. Chemokines in angiogenesis. Curr. Top. Microbiol. Immun. 2010, 341, 59-80.
46. Flad, H. D.; Brandt, E. Platelet-derived chemokines: Pathophysiology and therapeutic aspects. Cell. Mol. Life Sci. 2010, 67, 2363-2386.
47. Zlotnik, A.; Yoshie, O.; Nomiyama, H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006, 7, 243.
48. Oo, Y. H.; Adams, D. H. The role of chemokines in the recruitment of lymphocytes to the liver. J. Autoimmun. 2010, 34, 45-54.
49. Schall, T. J.; Proudfoot, A. E. I. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat. Publ. Gr. 2011, 11, 355-363.
50. Loetscher, P.; Pellegrino, A.; Gong, J. H.; Mattioli, I.; Loetscher, M.; Bardi, G.; Baggiolini, M.; Clark-Lewis, I. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 2001, 276, 2986-2991.
51. Nibbs, R. J. B.; Graham, G. J. Immune regulation by atypical chemokine receptors. Nat. Rev. Immun. 2013, 13, 815-829.
52. Fra, A. M.; Locati, M.; Otero, K.; Sironi, M.; Signorelli, P.; Massardi, M. L.; Gobbi, M.; Vecchi, A.; Sozzani, S.; Mantovani, A. Cutting edge: Scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J. Immunol. 2003, 170, 2279-2282.
53. Nibbs, R. J.; Wylie, S. M.; Yang, J.; Landau, N. R.; Graham, G. J. Cloning and characterization of a novel promiscuous human β-chemokine receptor D6. J. Biol. Chem. 1997, 272, 32078-32083.
54. Berres, M. L.; Trautwein, C.; Zaldivar, M. M.; Schmitz, P.; Pauels, K.; Lira, S. A.; Tacke, F.; Wasmuth, H. E. The chemokine scavenging receptor D6 limits acute toxic liver injury in vivo. Biol. Chem. 2009, 390, 1039-1045.
55. Wasmuth, H.; Tacke, F.; Trautwein, C. Chemokines in liver inflammation and fibrosis. Semin. Liver Dis. 2010, 30, 215-225.
56. Nemeth, E.; Baird, A. W.; O'Farrelly, C. Microanatomy of the liver immune system. Semin. Immunopathol. 2009, 31, 333-343.
57. Tiegs, G.; Lohse, A. W. Immune tolerance: What is unique about the liver. J. Autoimmun. 2010, 34, 1-6.
58. Bonecchi, R.; Bianchi, G.; Bordignon, P. P.; D'Ambrosio, D.; Lang, R.; Borsatti, A.; Sozzani, S.; Allavena, P.; Gray, P. A.; Mantovani, A.; et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 1998, 187, 129-134.
59. Crispe, I. N. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 2003, 3, 51-62.
60. Viola, A.; Luster, A. D. Chemokines and their receptors: Drug targets in immunity and inflammation. Ann. Rev. Pharmacol. Toxicol. 2008, 48, 171-197.
61. Zimmermann, H. W.; Tacke, F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm. Allerg. Drug Targets 2011, 10, 509-536.
62. Bautista, A. P. Chronic alcohol intoxication primes Kupffer cells and endothelial cells for enhanced CC-chemokine production and concomitantly suppresses phagocytosis and chemotaxis. Front. Biosci. 2002, 7, a117-a125.
63. Hokeness, K. L.; Kuziel, W. A.; Biron, C. A.; Salazar-Mather, T. P. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-α/β-induced inflammatory responses and antiviral defense in liver. J. Immunol. 2005, 174, 1549-1556.
64. Loetscher, P.; Uguccioni, M.; Bordoli, L.; Baggiolini, M.; Moser, B.; Chizzolini, C.; Dayer, J. M. CCR5 is characteristic of Th1 lymphocytes. Nature 1998, 391, 344-345.
65. Megjugorac, N. J.; Young, H. A.; Amrute, S. B.; Olshalsky, S. L.; Fitzgerald-Bocarsly, P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J. Leukoc. Biol. 2004, 75, 504-514.
66. Piqueras, B.; Connolly, J.; Freitas, H.; Palucka, A. K.; Banchereau, J. Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood 2006, 107, 2613-2618.
67. Salazar-Mather, T. P.; Lewis, C. A.; Biron, C. A. Type I interferons regulate inflammatory cell trafficking and macrophage inflammatory protein 1α delivery to the liver. J. Clin. Investig. 2002, 110, 321-330.
68. Salazar-Mather, T. P.; Orange, J. S.; Biron, C. A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J. Exp. Med. 1998, 187, 1-14.
69. Sallusto, F.; Schaerli, P.; Loetscher, P.; Schaniel, C.; Lenig, D.; Mackay, C. R.; Qin, S.; Lanzavecchia, A. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 1998, 28, 2760-2769.
70. Seki, E.; De Minicis, S.; Österreicher, C. H.; Kluwe, J.; Osawa, Y.; Brenner, D. A.; Schwabe, R. F. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat. Med. 2007, 13, 1324-1332.
71. Zimmermann, H. W.; Seidler, S.; Nattermann, J.; Gassler, N.; Hellerbrand, C.; Zernecke, A.; Tischendorf, J. J. W.; Luedde, T.; Weiskirchen, R.; Trautwein, C.; et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010, 5, e11049.
72. Carr, M. W.; Roth, S. J.; Luther, E.; Rose, S. S.; Springer, T. A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA 1994, 91, 3652-3656.
73. Decalf, J.; Fernandes, S.; Longman, R.; Ahloulay, M.; Audat, F.; Lefrerre, F.; Rice, C. M.; Pol, S.; Albert, M. L. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J. Exp. Med. 2007, 204, 2423-2437.
74. Fuentes, M. E.; Durham, S. K.; Swerdel, M. R.; Lewin, A. C.; Barton, D. S.; Megill, J. R.; Bravo, R.; Lira, S. A. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J. Immunol. 1995, 155, 5769-5776.
75. Gu, L.; Tseng, S.; Horner, R. M.; Tam, C.; Loda, M.; Rollins, B. J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404, 407-411.
76. Gunn, M. D.; Nelken, N. A.; Liao, X.; Williams, L. T. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J. Immunol. 1997, 158, 376-383.
77. Maghazachi, A. A.; al-Aoukaty, A.; Schall, T. J. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. J. Immunol. 1994, 153, 4969-4977.
78. Alferink, J.; Lieberam, I.; Reindl, W.; Behrens, A.; Weiss, S.; Hüser, N.; Gerauer, K.; Ross, R.; Reske-Kunz, A. B.; Ahmad-Nejad, P.; et al. Compartmentalized production of CCL17 in vivo: Strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen. J. Exp. Med. 2003, 197, 585-599.
79. Andrew, D. P.; Chang, M. S.; McNinch, J.; Wathen, S. T.; Rihanek, M.; Tseng, J.; Spellberg, J. P.; Elias, C. G. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J. Immunol. 1998, 161, 5027-5038.
80. Hirahara, K.; Liu, L.; Clark, R. A.; Yamanaka, K.-i.; Fuhlbrigge, R. C.; Kupper, T. S. The majority of human peripheral blood CD4+ CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J. Immunol. 2006, 177, 4488-4494.
81. Imai, T.; Nagira, M.; Takagi, S.; Kakizaki, M.; Nishimura, M.; Wang, J.; Gray, P. W.; Matsushima, K.; Yoshie, O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol. 1999, 11, 81-88.
82. Mariani, M.; Lang, R.; Binda, E.; Panina-Bordignon, P.; D'Ambrosio, D. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur. J. Immunol. 2004, 34, 231-240.
83. Sallusto, F.; Lenig, D.; Mackay, C. R.; Lanzavecchia, A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 1998, 187, 875-883.
84. Ahuja, S. K.; Murphy, P. M. The CXC chemokines growth-regulated oncogene GROα, GROβ, GROγ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 1996, 271, 20545-20550.
85. Clarke, C.; Kuboki, S.; Sakai, N.; Kasten, K. R.; Tevar, A. D.; Schuster, R.; Blanchard, J.; Caldwell, C. C.; Edwards, M. J.; Lentsch, A. B. CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia/reperfusion injury. Hepatology 2011, 53, 261-271.
86. Hess, C.; Means, T. K.; Autissier, P.; Woodberry, T.; Altfeld, M.; Addo, M. M.; Frahm, N.; Brander, C.; Walker, B. D.; Luster, A. D. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood 2004, 104, 3463-3471.
87. Heydtmann, M.; Adams, D. H. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 2009, 49, 676-688.
88. Huber, A. R.; Kunkel, S. L.; Todd, R. F.; Weiss, S. J. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991, 254, 99-102.
89. Matsushima, K.; Oppenheim, J. J. Interleukin 8 and MCAF: Novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine 1989, 1, 2-13.
90. Ohkubo, K.; Masumoto, T.; Horiike, N.; Onji, M. Induction of CINC (interleukin-8) production in rat liver by non-parenchymal cells. J. Gastroenterol. Hepatol. 1998, 13, 696-702.
91. Pelletier, M.; Maggi, L.; Micheletti, A.; Lazzeri, E.; Tamassia, N.; Costantini, C.; Cosmi, L.; Lunardi, C.; Annunziato, F.; Romagnani, S.; et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 2010, 115, 335-343.
92. Strieter, R. M.; Kunkel, S. L.; Showell, H. J.; Remick, D. G.; Phan, S. H.; Ward, P. A.; Marks, R. M. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β. Science 1989, 243, 1467-1469.
93. Thornton, A. J.; Strieter, R. M.; Lindley, I.; Baggiolini, M.; Kunkel, S. L. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J. Immunol. 1990, 144, 2609-2613.
94. Van Damme, J.; Decock, B.; Lenaerts, J. P.; Conings, R.; Bertini, R.; Mantovani, A.; Billiau, A. Identification by sequence analysis of chemotactic factors for monocytes produced by normal and transformed cells stimulated with virus, double-stranded RNA or cytokine. Eur. J. Immunol. 1989, 19, 2367-2373.
95. Wagoner, J.; Austin, M.; Green, J.; Imaizumi, T.; Casola, A.; Brasier, A.; Khabar, K. S. A.; Wakita, T.; Gale, M.; Polyak, S. J. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J. Virol. 2007, 81, 309-318.
96. Brownell, J.; Polyak, S. J. Molecular pathways: Hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin. Cancer Res. 2013, 19, 1347-1352.
97. Cole, K. E.; Strick, C. A.; Paradis, T. J.; Ogborne, K. T.; Loetscher, M.; Gladue, R. P.; Lin, W.; Boyd, J. G.; Moser, B.; Wood, D. E.; et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 1998, 187, 2009-2021.
98. Crispe, I. N. Migration of lymphocytes into hepatic sinusoids. J. Hepatol. 2012, 57, 218-220.
99. Helbig, K. J.; Ruszkiewicz, A.; Semendric, L.; Harley, H. A. J.; McColl, S. R.; Beard, M. R. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 2004, 39, 1220-1229.
100. Hokeness, K. L.; Deweerd, E. S.; Munks, M. W.; Lewis, C. A.; Gladue, R. P.; Salazar-Mather, T. P. CXCR3-dependent recruitment of antigen-specific T lymphocytes to the liver during murine cytomegalovirus infection. J. Virol. 2007, 81, 1241-1250.
101. Mantovani, A.; Cassatella, M. A.; Costantini, C.; Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 2011, 11, 519-531.
102. Lasagni, L.; Francalanci, M.; Annunziato, F.; Lazzeri, E.; Giannini, S.; Cosmi, L.; Sagrinati, C.; Mazzinghi, B.; Orlando, C.; Maggi, E.; et al. An Alternatively spliced bariant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 2003, 197, 1537-1549.
103. Mueller, A.; Meiser, A.; McDonagh, E. M.; Fox, J. M.; Petit, S. J.; Xanthou, G.; Williams, T. J.; Pease, J. E. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J. Leukoc. Biol. 2008, 83, 875-882.
104. Bernhagen, J.; Krohn, R.; Lue, H.; Gregory, J. L.; Zernecke, A.; Koenen, R. R.; Dewor, M.; Georgiev, I.; Schober, A.; Leng, L.; et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 2007, 13, 587-596.
105. Burns, J. M.; Summers, B. C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M. E. T.; Sunshine, M. J.; Littman, D. R.; Kuo, C. J.; et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203, 2201-2213.
106. Gupta, S. K.; Pillarisetti, K. Cutting edge: CXCR4-Lo: Molecular cloning and functional expression of a novel human CXCR4 splice variant. J. Immunol. 1999, 163, 2368-2372.
107. Hong, F.; Tuyama, A.; Lee, T. F.; Loke, J.; Agarwal, R.; Cheng, X.; Garg, A.; Fiel, M. I.; Schwartz, M.; Walewski, J.; et al. Hepatic stellate cells express functional CXCR4: Role in stromal cell-derived factor-1α-mediated stellate cell activation. Hepatology 2009, 49, 2055-2067.
108. Levoye, A.; Balabanian, K.; Baleux, F.; Bachelerie, F.; Lagane, B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113, 6085-6093.
109. Maksym, R. B.; Tarnowski, M.; Grymula, K.; Tarnowska, J.; Wysoczynski, M.; Liu, R.; Czerny, B.; Ratajczak, J.; Kucia, M.; Ratajczak, M. Z. The role of stromal-derived factor-1-CXCR7 axis in development and cancer. Eur. J. Pharmacol. 2009, 625, 31-40.
110. Saini, V.; Marchese, A.; Majetschak, M. CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J. Biol. Chem. 2010, 285, 15566-15576.
111. Geissmann, F.; Cameron, T. O.; Sidobre, S.; Manlongat, N.; Kronenberg, M.; Briskin, M. J.; Dustin, M. L.; Littman, D. R. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005, 3, e113.
112. Germanov, E.; Veinotte, L.; Cullen, R.; Chamberlain, E.; Butcher, E. C.; Johnston, B. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J. Immunol. 2008, 181, 81-91.
113. Heydtmann, M.; Lalor, P. F.; Eksteen, J. A.; Hubscher, S. G.; Briskin, M.; Adams, D. H. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J. Immunol. 2005, 174, 1055-1062.
114. Shields, P. L.; Morland, C. M.; Salmon, M.; Qin, S.; Hubscher, S. G.; Adams, D. H. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 1999, 163, 6236-6243.
115. Nguyen, N.; de Esch, C.; Cameron, B.; Kumar, R. K.; Zekry, A.; Lloyd, A. R. Positioning of leukocyte subsets in the portal and lobular compartments of HCV-infected liver correlates with local chemokine expression. J. Gastroenterol. Hepatol. 2014, 2014, doi: 10. 1111/jgh. 12462.
116. Zeremski, M.; Petrovic, L. M.; Talal, A. H. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J. Viral. Hepat. 2007, 14, 675-687.
117. Lichterfeld, M.; Leifeld, L.; Nischalke, H. D.; Rockstroh, J. K.; Hess, L.; Sauerbruch, T.; Spengler, U. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J. Infect. Dis. 2002, 185, 1803-1807.
118. Apolinario, A.; Majano, P. L.; Lorente, R.; Nunez, O.; Clemente, G.; Garcia-Monzon, C. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: Evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J. Viral. Hepat. 2005, 12, 27-37.
119. Sillanpaa, M.; Kaukinen, P.; Melen, K.; Julkunen, I. Hepatitis C virus proteins interfere with the activation of chemokine gene promoters and downregulate chemokine gene expression. J. Gen. Virol. 2008, 89, 432-443.
120. Brenndorfer, E. D.; Brass, A.; Karthe, J.; Ahlen, G.; Bode, J. G.; Sallberg, M. Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy. J. Immunol. 2014, 192, 1671-80.
121. Asselah, T.; Bieche, I.; Laurendeau, I.; Paradis, V.; Vidaud, D.; Degott, C.; Martinot, M.; Bedossa, P.; Valla, D.; Vidaud, M.; et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005, 129, 2064-2075.
122. Zhdanov, K. V.; Gusev, D. A.; Chirskii, V. S.; Sysoev, K. A.; Iakubovskaia, L. A.; Shakhmanov, D. M.; Totolian, A. A. Chronic HCV-infection and expression of mRNA of CC-chemokines and their receptors. Zhurnal Mikrobiol. Epidemiol. Immunobiol. 2008, 2008, 73-78. (In Russian).
123. Brenndorfer, E. D.; Weiland, M.; Frelin, L.; Derk, E.; Ahlen, G.; Jiao, J.; Bode, J. G.; Sallberg, M. Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C. Hepatology 2010, 52, 1553-1563.
124. Soo, H. M.; Garzino-Demo, A.; Hong, W.; Tan, Y. H.; Tan, Y. J.; Goh, P.; Lim, S. G.; Lim, S. P. Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology 2002, 303, 253-277.
125. Brenndorfer, E. D.; Brass, A.; Soderholm, J.; Frelin, L.; Aleman, S.; Bode, J. G.; Sallberg, M. Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production. Gut 2012, 61, 589-596.
126. Riezu-Boj, J. I.; Larrea, E.; Aldabe, R.; Guembe, L.; Casares, N.; Galeano, E.; Echeverria, I.; Sarobe, P.; Herrero, I.; Sangro, B.; et al. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. J. Hepatol. 2011, 54, 422-431.
127. Gruener, N. H.; Lechner, F.; Jung, M. C.; Diepolder, H.; Gerlach, T.; Lauer, G.; Walker, B.; Sullivan, J.; Phillips, R.; Pape, G. R.; et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J. Virol. 2001, 75, 5550-5558.
128. Kaplanski, G.; Farnarier, C.; Payan, M. J.; Bongrand, P.; Durand, J. M. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig. Dis. Sci. 1997, 42, 2277-2284.
129. Polyak, S. J.; Khabar, K. S.; Rezeiq, M.; Gretch, D. R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 2001, 75, 6209-6211.
130. Bataller, R.; Paik, Y. H.; Lindquist, J. N.; Lemasters, J. J.; Brenner, D. A. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004, 126, 529-540.
131. Kadoya, H.; Nagano-Fujii, M.; Deng, L.; Nakazono, N.; Hotta, H. Nonstructural proteins 4A and 4B of hepatitis C virus transactivate the interleukin 8 promoter. Microbiol. Immunol. 2005, 49, 265-273.
132. Zeremski, M.; Petrovic, L. M.; Chiriboga, L.; Brown, Q. B.; Yee, H. T.; Kinkhabwala, M.; Jacobson, I. M.; Dimova, R.; Markatou, M.; Talal, A. H. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008, 48, 1440-1450.
133. Helbig, K. J.; Ruszkiewicz, A.; Lanford, R. E.; Berzsenyi, M. D.; Harley, H. A.; McColl, S. R.; Beard, M. R. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J. Virol. 2009, 83, 836-846.
134. Larrubia, J. R.; Calvino, M.; Benito, S.; Sanz-de-Villalobos, E.; Perna, C.; Perez-Hornedo, J.; Gonzalez-Mateos, F.; Garcia-Garzon, S.; Bienvenido, A.; Parra, T. The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. J. Hepatol. 2007, 47, 632-641.
135. Kaukinen, P.; Sillanpaa, M.; Kotenko, S.; Lin, R.; Hiscott, J.; Melen, K.; Julkunen, I. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virol. J. 2006, 3, 66.
136. Zekri, A. R.; Bahnassy, A. A.; Mohamed, W. S.; Alam El-Din, H. M.; Shousha, H. I.; Zayed, N.; Eldahshan, D. H.; Abdel-Aziz, A. O. Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon. Virol. J. 2013, 10, 218.
137. Brownell, J.; Wagoner, J.; Lovelace, E. S.; Thirstrup, D.; Mohar, I.; Smith, W.; Giugliano, S.; Li, K.; Crispe, I. N.; Rosen, H. R.; et al. Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. J. Hepatol. 2013, 59, 701-708.
138. Zeremski, M.; Hooker, G.; Shu, M. A.; Winkelstein, E.; Brown, Q.; des Jarlais, D. C.; Tobler, L. H.; Rehermann, B.; Busch, M. P.; Edlin, B. R.; et al. Induction of CXCR3-and CCR5-associated chemokines during acute hepatitis C virus infection. J. Hepatol. 2011, 55, 545-553.
139. Harvey, C. E.; Post, J. J.; Palladinetti, P.; Freeman, A. J.; Ffrench, R. A.; Kumar, R. K.; Marinos, G.; Lloyd, A. R. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J. Leukoc. Biol. 2003, 74, 360-369.
140. Helbig, K. J.; George, J.; Beard, M. R. A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro. J. Clin. Virol. 2005, 32, 137-143.
141. Spengler, U.; Nattermann, J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin. Sci. 2007, 112, 141-155.
142. Wang, J.; Holmes, T. H.; Cheung, R.; Greenberg, H. B.; He, X. S. Expression of chemokine receptors on intrahepatic and peripheral lymphocytes in chronic hepatitis C infection: Its relationship to liver inflammation. J. Infect. Dis. 2004, 190, 989-997.
143. Northfield, J. W.; Kasprowicz, V.; Lucas, M.; Kersting, N.; Bengsch, B.; Kim, A.; Phillips, R. E.; Walker, B. D.; Thimme, R.; Lauer, G.; et al. CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation. Hepatology 2008, 47, 396-406.
144. Apolinario, A.; Majano, P. L.; Alvarez-Perez, E.; Saez, A.; Lozano, C.; Vargas, J.; Garcia-Monzon, C. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: Relationship with the histological activity of liver disease. Am. J. Gastroenterol. 2002, 97, 2861-2870.
145. Palmer, C.; Corpuz, T.; Guirguis, M.; O'Toole, S.; Yan, K.; Bu, Y.; Jorgenson, J.; Talbot, M.; Loi, K.; Lloyd, A.; et al. The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. Gut 2010, 59, 397-404.
146. Mihm, S.; Schweyer, S.; Ramadori, G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-γ and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J. Med. Virol. 2003, 70, 562-570.
147. Woitas, R. P.; Ahlenstiel, G.; Iwan, A.; Rockstroh, J. K.; Brackmann, H. H.; Kupfer, B.; Matz, B.; Offergeld, R.; Sauerbruch, T.; Spengler, U. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology 2002, 122, 1721-1728.
148. Brenndorfer, E. D.; Karthe, J.; Frelin, L.; Cebula, P.; Erhardt, A.; Schulteam Esch, J.; Hengel, H.; Bartenschlager, R.; Sallberg, M.; Haussinger, D.; et al. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 2009, 49, 1810-1820.
149. Rahbin, N.; Frelin, L.; Aleman, S.; Hultcrantz, R.; Sallberg, M.; Brenndorfer, E. D. Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients. Biochem. Biophys. Res. Commun. 2013, 433, 31-35.
150. Shimoda, K.; Begum, N. A.; Shibuta, K.; Mori, M.; Bonkovsky, H. L.; Banner, B. F.; Barnard, G. F. Interleukin-8 and hIRH (SDF1-α/PBSF) mRNA expression and histological activity index in patients with chronic hepatitis C. Hepatology 1998, 28, 108-115.
151. Tsukada, S.; Parsons, C. J.; Rippe, R. A. Mechanisms of liver fibrosis. Clin. Chim. Acta 2006, 364, 33-60.
152. Imamura, M.; Ogawa, T.; Sasaguri, Y.; Chayama, K.; Ueno, H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 2005, 128, 138-146.
153. Muhlbauer, M.; Bosserhoff, A. K.; Hartmann, A.; Thasler, W. E.; Weiss, T. S.; Herfarth, H.; Lock, G.; Scholmerich, J.; Hellerbrand, C. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003, 125, 1085-1093.
154. Schwabe, R. F.; Bataller, R.; Brenner, D. A. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285, G949-G958.
155. Seki, E.; De Minicis, S.; Gwak, G. Y.; Kluwe, J.; Inokuchi, S.; Bursill, C. A.; Llovet, J. M.; Brenner, D. A.; Schwabe, R. F. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Investig. 2009, 119, 1858-1870.
156. Radaeva, S.; Sun, R.; Jaruga, B.; Nguyen, V. T.; Tian, Z.; Gao, B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006, 130, 435-452.
157. Kawarabayashi, N.; Seki, S.; Hatsuse, K.; Ohkawa, T.; Koike, Y.; Aihara, T.; Habu, Y.; Nakagawa, R.; Ami, K.; Hiraide, H.; et al. Decrease of CD56+ T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000, 32, 962-969.
158. Muhanna, N.; Doron, S.; Wald, O.; Horani, A.; Eid, A.; Pappo, O.; Friedman, S. L.; Safadi, R. Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology 2008, 48, 963-977.
159. Jeong, W. I.; Park, O.; Radaeva, S.; Gao, B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006, 44, 1441-1451.
160. Wynn, T. A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. 2004, 4, 583-594.
161. Chew, V.; Chen, J.; Lee, D.; Loh, E.; Lee, J.; Lim, K. H.; Weber, A.; Slankamenac, K.; Poon, R. T.; Yang, H.; et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012, 61, 427-438.
162. Fu, J.; Xu, D.; Liu, Z.; Shi, M.; Zhao, P.; Fu, B.; Zhang, Z.; Yang, H.; Zhang, H.; Zhou, C.; et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132, 2328-2339.
163. Hoechst, B.; Ormandy, L. A.; Ballmaier, M.; Lehner, F.; Kruger, C.; Manns, M. P.; Greten, T. F.; Korangy, F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells. Gastroenterology 2008, 135, 234-243.
164. Ajuebor, M. N.; Hogaboam, C. M.; Le, T.; Proudfoot, A. E.; Swain, M. G. CCL3/MIP-1α is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4+ T cells to the liver. Eur. J. Immunol. 2004, 34, 2907-2918.
165. Ajuebor, M. N.; Wondimu, Z.; Hogaboam, C. M.; Le, T.; Proudfoot, A. E.; Swain, M. G. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am. J. Pathol. 2007, 170, 1975-1988.
166. Moreno, C.; Gustot, T.; Nicaise, C.; Quertinmont, E.; Nagy, N.; Parmentier, M.; Le Moine, O.; Deviere, J.; Louis, H. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005, 42, 854-862.
167. Mitchell, C.; Couton, D.; Couty, J. P.; Anson, M.; Crain, A. M.; Bizet, V.; Renia, L.; Pol, S.; Mallet, V.; Gilgenkrantz, H. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am. J. Pathol. 2009, 174, 1766-1775.
168. Ishiwata, Y.; Yokochi, S.; Hashimoto, H.; Ninomiya, F.; Suzuki, T. Protection against concanavalin A-induced murine liver injury by the organic germanium compound, propagermanium. Scand. J. Immunol. 1998, 48, 605-614.
169. Yokochi, S.; Ishiwata, Y.; Hashimoto, H.; Ninomiya, F.; Suzuki, T. Hepatoprotective effect of propagermanium on Corynebacterium parvum and lipopolysaccharide-induced liver injury in mice. Scand. J. Immunol. 1998, 48, 183-191.
170. Hogaboam, C. M.; Bone-Larson, C. L.; Steinhauser, M. L.; Matsukawa, A.; Gosling, J.; Boring, L.; Charo, I. F.; Simpson, K. J.; Lukacs, N. W.; Kunkel, S. L. Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. Am. J. Pathol. 2000, 156, 1245-1252.
171. Wiederholt, T.; von Westernhagen, M.; Zaldivar, M. M.; Berres, M. L.; Schmitz, P.; Hellerbrand, C.; Muller, T.; Berg, T.; Trautwein, C.; Wasmuth, H. E. Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. Hum. Immunol. 2008, 69, 861-866.
172. Jaeschke, H.; Hasegawa, T. Role of neutrophils in acute inflammatory liver injury. Liver Int. 2006, 26, 912-919.
173. Kuboki, S.; Shin, T.; Huber, N.; Eismann, T.; Galloway, E.; Schuster, R.; Blanchard, J.; Edwards, M. J.; Lentsch, A. B. Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice. Hepatology 2008, 48, 1213-1223.
174. Bertini, R.; Allegretti, M.; Bizzarri, C.; Moriconi, A.; Locati, M.; Zampella, G.; Cervellera, M. N.; di Cioccio, V.; Cesta, M. C.; Galliera, E.; et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc. Natl. Acad. Sci. USA 2004, 101, 11791-11796.
175. Erhardt, A.; Wegscheid, C.; Claass, B.; Carambia, A.; Herkel, J.; Mittrucker, H. W.; Panzer, U.; Tiegs, G. CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis. J. Immunol. 2011, 186, 5284-5293.
176. Zaldivar, M. M.; Berres, M. L.; Sahin, H.; Nellen, A.; Heinrichs, D.; Schmitz, P.; Gassler, N.; Streetz, K. L.; Trautwein, C.; Wasmuth, H. E. The chemokine receptor CXCR3 limits injury after acute toxic liver damage. Lab. Investig. 2012, 92, 724-734.
177. Zhai, Y.; Shen, X. D.; Hancock, W. W.; Gao, F.; Qiao, B.; Lassman, C.; Belperio, J. A.; Strieter, R. M.; Busuttil, R. W.; Kupiec-Weglinski, J. W. CXCR3+ CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury. J. Immunol. 2006, 176, 6313-6322.
178. Ajuebor, M. N.; Jin, Y.; Gremillion, G. L.; Strieter, R. M.; Chen, Q.; Adegboyega, P. A. γδT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk. J. Virol. 2008, 82, 9564-9576.
179. Wehr, A.; Baeck, C.; Heymann, F.; Niemietz, P. M.; Hammerich, L.; Martin, C.; Zimmermann, H. W.; Pack, O.; Gassler, N.; Hittatiya, K.; et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J. Immunol. 2013, 190, 5226-5236.
180. Xu, H. B.; Gong, Y. P.; Cheng, J.; Chu, Y. W.; Xiong, S. D. CXCL16 participates in pathogenesis of immunological liver injury by regulating T lymphocyte infiltration in liver tissue. World J. Gastroenterol. 2005, 11, 4979-4985.
181. Yang, S. J.; IglayReger, H. B.; Kadouh, H. C.; Bodary, P. F. Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia 2009, 52, 972-981.
182. Tamura, Y.; Sugimoto, M.; Murayama, T.; Minami, M.; Nishikaze, Y.; Ariyasu, H.; Akamizu, T.; Kita, T.; Yokode, M.; Arai, H. C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice. J. Ather. Thromb. 2010, 17, 219-228.
183. Barashi, N.; Weiss, I. D.; Wald, O.; Wald, H.; Beider, K.; Abraham, M.; Klein, S.; Goldenberg, D.; Axelrod, J.; Pikarsky, E.; et al. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology 2013, 58, 1021-1030.
184. Karlmark, K. R.; Weiskirchen, R.; Zimmermann, H. W.; Gassler, N.; Ginhoux, F.; Weber, C.; Merad, M.; Luedde, T.; Trautwein, C.; Tacke, F. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50, 261-274.
185. Seki, E.; de Minicis, S.; Inokuchi, S.; Taura, K.; Miyai, K.; van Rooijen, N.; Schwabe, R. F.; Brenner, D. A. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009, 50, 185-197.
186. Baeck, C.; Wehr, A.; Karlmark, K. R.; Heymann, F.; Vucur, M.; Gassler, N.; Huss, S.; Klussmann, S.; Eulberg, D.; Luedde, T.; et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012, 61, 416-426.
187. Stefanovic, L.; Brenner, D. A.; Stefanovic, B. Direct hepatotoxic effect of KC chemokine in the liver without infiltration of neutrophils. Exp. Biol. Med. 2005, 230, 573-586.
188. Zimmermann, H. W.; Seidler, S.; Gassler, N.; Nattermann, J.; Luedde, T.; Trautwein, C.; Tacke, F. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One 2011, 6, e21381.
189. Zaldivar, M. M.; Pauels, K.; von Hundelshausen, P.; Berres, M. L.; Schmitz, P.; Bornemann, J.; Kowalska, M. A.; Gassler, N.; Streetz, K. L.; Weiskirchen, R.; et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010, 51, 1345-1353.
190. Hintermann, E.; Bayer, M.; Pfeilschifter, J. M.; Luster, A. D.; Christen, U. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J. Autoimmun. 2010, 35, 424-435.
191. Wasmuth, H. E.; Lammert, F.; Zaldivar, M. M.; Weiskirchen, R.; Hellerbrand, C.; Scholten, D.; Berres, M. L.; Zimmermann, H.; Streetz, K. L.; Tacke, F.; et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009, 137, 309-319.
192. Ding, B. S.; Cao, Z.; Lis, R.; Nolan, D. J.; Guo, P.; Simons, M.; Penfold, M. E.; Shido, K.; Rabbany, S. Y.; Rafii, S. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 2014, 505, 97-102.
193. Yang, X.; Lu, P.; Fujii, C.; Nakamoto, Y.; Gao, J. L.; Kaneko, S.; Murphy, P. M.; Mukaida, N. Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression. Int. J. Cancer 2006, 118, 1869-1876.
194. Kapanadze, T.; Gamrekelashvili, J.; Ma, C.; Chan, C.; Zhao, F.; Hewitt, S.; Zender, L.; Kapoor, V.; Felsher, D. W.; Manns, M. P.; et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J. Hepatol. 2013, 59, 1007-1013.
195. Chen, Y.; Huang, Y.; Reiberger, T.; Duyverman, A. M.; Huang, P.; Samuel, R.; Hiddingh, L.; Roberge, S.; Koppel, C.; Lauwers, G. Y.; et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1α/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice. Hepatology 2014, 2014, doi: 10. 1002/hep. 26790.
196. Zheng, K.; Li, H. Y.; Su, X. L.; Wang, X. Y.; Tian, T.; Li, F.; Ren, G. S. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 2010, 29, 31.
197. Fatkenheuer, G.; Pozniak, A. L.; Johnson, M. A.; Plettenberg, A.; Staszewski, S.; Hoepelman, A. I.; Saag, M. S.; Goebel, F. D.; Rockstroh, J. K.; Dezube, B. J.; et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11, 1170-1172.
198. Ramos, C. D.; Canetti, C.; Souto, J. T.; Silva, J. S.; Hogaboam, C. M.; Ferreira, S. H.; Cunha, F. Q. MIP-1α [CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-α and LTB4. J. Leukoc. Biol. 2005, 78, 167-177.
199. Bonecchi, R.; Polentarutti, N.; Luini, W.; Borsatti, A.; Bernasconi, S.; Locati, M.; Power, C.; Proudfoot, A.; Wells, T. N.; Mackay, C.; et al. Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-γ in human neutrophils. J. Immunol. 1999, 162, 474-479.